Citigroup Initiates Coverage On Xenon Pharmaceuticals With Buy Rating, Announces Price Target of $62
Citigroup Initiates Coverage On Xenon Pharmaceuticals With Buy Rating, Announces Price Target of $62
花旗集團以買入評級啓動對Xenon Pharmicals的報道，宣佈目標股價爲62美元
Citigroup analyst David Hoang initiates coverage on Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy rating and announces Price Target of $62.
花旗集團分析師大衛·霍恩開始對Xenon Pharmicals（納斯達克股票代碼：XENE）進行報道，評級爲買入，並宣佈目標股價爲62美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。